This trial is conducted in Europe. The aim of the trial is to investigate the influence of oral semaglutide on pharmacokinetics (the exposure of the trial drug in the body) of ethinylestradiol and levonorgestrel in an oral contraceptive combination drug in healthy postmenopausal females.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Oral administration once daily alone or together with oral contraceptive.
Oral administration once daily together with oral contraceptive.
Oral administration once daily alone or together with oral semaglutide or SNAC.
Novo Nordisk Investigational Site
Berlin, Germany
Area under the ethinylestradiol plasma concentration-time curve during a dosing interval (0-24 hours) at steady state
Time frame: On day 8 (OC alone), day 24 (OC with SNAC) and day 82 (OC with oral semaglutide at steady state)
Area under the levonorgestrel plasma concentration-time curve during a dosing interval (0-24 hours) at steady state
Time frame: On day 8 (OC alone), day 24 (OC with SNAC) and day 82 (OC with oral semaglutide at steady state)
Maximum observed ethinylestradiol plasma concentration during a dosing interval (0-24 hours) at steady state
Time frame: On day 8 (OC alone), day 24 (OC with SNAC) and day 82 (OC with oral semaglutide at steady state)
Maximum observed levonorgestrel plasma concentration during a dosing interval 0-24 hours) at steady state
Time frame: On day 8 (OC alone), day 24 (OC with SNAC) and day 82 (OC with oral semaglutide at steady state)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.